TY  - CHAP
M1  - Book, Section
TI  - Drug Therapy for Hypercholesterolemia and Dyslipidemia
A1  - Bersot, Thomas P.
A2  - Brunton, Laurence L.
A2  - Chabner, Bruce A.
A2  - Knollmann, Björn C.
Y1  - 2015
N1  - 
T2  - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e
AB  - Hyperlipidemia  is  a  major  cause  of  atherosclerosis  and  atherosclerosis-induced  conditions,  such  as  coronary  heart  disease  (CHD),  ischemic  cerebrovascular  disease,  and  peripheral  vascular  disease.  Although  the  incidence  of  these  atherosclerosis-related  cardiovascular  disease  (CVD)  events  has  declined  in  the  U.S.,  these  conditions  cause  morbidity  or  mortality  in  a  majority  of  middle-aged  or  older  adults  and  account  for  about  one-third  of  all  deaths  of  persons  in  this  age  range.  The  incidence  and  absolute  number  of  annual  events  will  likely  increase  over  the  next  decade  because  of  the  epidemic  of  obesity  and  the  aging  of  the  U.S.  population.  Dyslipidemias,  including  hyperlipidemia  (hypercholesterolemia)  and  low  levels  of  high-density-lipoprotein  cholesterol  (HDL-C),  are  major  causes  of  increased  atherogenic  risk;  both  genetic  disorders  and  lifestyle  (sedentary  behavior  and  diets  high  in  calories,  saturated  fat,  and  cholesterol)  contribute  to  the  dyslipidemias  seen  in  countries  around  the  world.  For  many  individuals,  alterations  in  lifestyle  have  a  far  greater  potential  for  reducing  vascular  disease  risk  and  at  a  lower  cost  than  drug  therapy.  When  pharmacotherpy  is  indicated,  providers  can  choose  from  multiple  agents  with  proven  efficacy.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2023/05/31
UR  - accessbiomedicalscience.mhmedical.com/content.aspx?aid=1127868218
ER  -